HEALTH PLANS
UNIVERSITY OF UTAH

MEDICAL PHARMACY PRIOR AUTHORIZATION REQUEST FORM
OXLUMO™

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 801-213-1547. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans: 855-869-4769, Commercial Groups: 855-859-4892, MHC: 855-885-7695, Advantage U Part B: 888-605-0858

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		HCPCS Code:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: ☐ Oxlumo™ (lumasiran)

Dosing/Frequency:_____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Is the request made by, or in consultation with, a physician who specializes in the treatment of primary hyperoxaluria type 1 (PH1)?	☐	☐	
2. Does the member have a diagnosis of PH1 confirmed by both of the following: • Metabolic testing shows elevated urinary oxalate excretion persistently > 0.7mmol/1.73m^2/day OR for those less than 6 years of age a urinary oxalate/serum creatinine ratio > the ULN for the member's age • Genetic testing confirms a mutation in the alanine glyoxylate aminotransferase (AGXT) gene	☐	☐	**Please provide documentation**
3. Has the member received a liver transplant?	☐	☐	
4. Has the prescriber educated the member about diet, such as avoiding oxalate rich foods (e.g. chocolate, leafy green vegetables, black teas, nuts, star fruit)?	☐	☐	**Please provide documentation**
5. Has the member tried and failed, or has a contraindication/intolerance to, large fluid intake resulting in a high urinary output (> 3 L/day/1.73m^2)?	☐	☐	**Please provide documentation**

6. Has the member tried and failed, is currently taking, or has a contraindication/intolerance to, calcium-oxalate crystallization inhibitors (e.g. potassium citrate-citric acid, orthophosphate, magnesium oxide)?	☐	☐	**Please provide documentation**
7. Has the member tried and failed, is currently taking, or has a contraindication/intolerance to, pyridoxine (Vitamin B6) for ≥ 3 months without a positive response (defined as a reduction of > 30% in urinary oxalate excretion)?	☐	☐	**Please provide documentation**
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	☐	☐	
2. Has the member had a positive response to therapy with a significant reduction from baseline in urinary oxalate levels or for those <6 years of age a decrease in urinary oxalate/serum creatinine ratio?	☐	☐	**Please provide documentation**
3. Has the member experienced unacceptable drug toxicity to therapy?	☐	☐	
4. Has the member received a liver transplant?	☐	☐	
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM- M035
Origination Date: 12/20/2020
Reviewed/Revised Date: 05/19/2021
Next Review Date: 05/19/2022
Current Effective Date: 06/01/2021